Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Tolerability Check

On the downside: throat and liver

    • Neurology
    • Partner Content
    • RX
  • 4 minute read

In terms of tolerability, ozanimod compares favorably with other sphingosine-1-phosphate receptor modulators [1–3]*. In the pivotal studies, drop-out rates due to adverse events were approximately 3%, with comparable rates in each of the different treatment groups. The adverse drug reactions most commonly observed during ozanimod therapy were nasopharyngitis, upper respiratory tract infections, urinary tract infections, elevated alanine aminotransferase and γGT levels, hypertension, and headache.

In both phase III trials conducted, the most common reasons given for discontinuation were “voluntary withdrawal ” and side effects [2,3]. Study discontinuations directly related to adverse drug events occurred in 1.5% and 2.9%, respectively, in the ozanimod therapy groups and in 3.6% in the interferon therapy group in the SUNBEAM study with a minimum duration of 12 months (Table 1). In the RADIANCE trial with an intervention duration of 24 months, drop-outs directly attributable to adverse events were estimated to be about 3% in the intervention groups and 4.1% in the control group. Thus, therapy with interferon β1a resulted in the greatest number of clearly side-effect-associated treatment discontinuations in both cohorts, although the tolerability of the new agent appears to be good [2,3].

Nasopharyngitis as the most common side effect

Patients who experienced adverse drug reactions during pivotal trials most commonly dealt with nasopharyngitis [2,3]. Other infectious diseases such as upper respiratory tract infections, urinary tract infections or isolated pharygitis occurred somewhat less frequently with mostly mild courses. Elevations in liver enzymes, particularly ALT and γGT, were observed significantly more frequently with ozanimod therapy than with interferon β1a treatment in both phase III studies. Therefore, caution is advised in patients with liver failure and the drug is contraindicated in individuals with Child- Pugh class C [4]. Other side effects included hypertension, which increased especially in the RADIANCE study, hypercholesterolemia, headache, back pain, arthralgias, fatigue, and upper abdominal pain (Overview 1). Under close ophthalmologic monitoring, rare cases of macular edema occurred in both phase III trials [2,3]. While a total of 5 patients were affected in the RADIANCE cohort, 2 of whom received interferon β1a, exactly one participant per study arm developed the condition in the SUNBEAM study. In all cases, risk factors or causative comorbidities such as choroidopathies existed before therapy. In each case, treatment was discontinued immediately after diagnosis.

To date, the frequencies of adverse drug reactions are consistent with those observed in the two active-controlled clinical trials [5]. Nevertheless, due to the relatively recent introduction of the drug, close further monitoring, as conducted by the current open-label study DAYBREAK [5] and, of course, the drug regulatory authorities, is important. The bottom line is that infections are the most common side effects, which may be explained considering the mode of action with consecutive downregulation of the immune system.

Cost-benefit calculation in comparison

So far, only an indirect comparison by Swallow E et al. exists, which compares ozanimod with similar drugs such as the S1P receptor modulator fingolimod [1]*. This is favorable not only for the safety profile, but also with respect to the tolerability and thus the cost-benefit profile of the new agent.

After one year of therapy, there were significantly fewer adverse drug reactions and liver enzyme elevations, as well as greater mean lymphocyte counts under treatment with Ozanimod [1]. Fewer side effects were also observed with Ozanimod therapy when comparing agents at 2 years. In particular, liver infections, liver elevations, and bradycardia occurred less frequently during treatment with ozanimod. The spectrum of adverse drug reactions was comparable for both drugs. In the pivotal studies on fingolimod, there were significantly more study discontinuations due to side effects overall, supporting the thesis of comparatively better tolerability of ozanimod.

A direct comparison with alternative agents, also with regard to drug tolerance, is currently still pending and long-term data must be awaited. However, ozanimod appears to be a well-tolerated agent, as indicated by the data to date.

* which occurred in >2% of patients on ozanimod therapy with an incidence at least 1% higher than in the interferon group OZA=ozanimod; IFN=interferon beta-1a

Literature

Swallow E, Patterson-Lomba O, Yin L, et al: Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis. J Comp Eff Res. 2020; 9(4): 275-285.
2 Cohen JA, Comi G, Selmaj KW, et al: Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019; 18(11): 1021-1033.
3 Comi G, Kappos L, Selmaj KW, et al: Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019; 18(11): 1009-1020.
4. technical information Zeposia 2020, as of July 2020, www.swissmedicinfo.ch
5 Selmaj KW, et al: Long-term Efficacy of Ozanimod in Relapsing Multiple Sclerosis in DAYBREAK: An Open-Label Extension of the Phase 3 SUNBEAM and RADIANCE Trials. 6th Congress of the European Academy of Neurology, Sept 2020; Virtual presentation.
Partner
  • 2000px-bristol-myers_squibb_logo
Related Topics
  • MS Therapy in Transition
Previous Article
  • System therapy for atopic dermatitis

What biologics and JAK inhibitors are currently on the research horizon?

  • Allergology and clinical immunology
  • Congress Reports
  • Dermatology and venereology
  • RX
  • Studies
View Post
Next Article
  • Practice Check

Ozanimod in clinical routine

  • Neurology
  • Partner Content
  • RX
View Post
You May Also Like
View Post
  • 12 min
  • Evidence, effectiveness and practical implications

Medicinal plants for allergic rhinitis

    • RX
    • Allergology and clinical immunology
    • Education
    • General Internal Medicine
    • ORL
    • Pharmaceutical medicine
    • Phytotherapy
    • Studies
View Post
  • 15 min
  • Current status and future prospects

Cell and gene therapies in modern cardiology

    • Cardiology
    • Education
    • Genetics
    • RX
    • Studies
View Post
  • 14 min
  • Patient-oriented recommendations for action

Effect of heat on diabetes technology

    • RX
    • CME continuing education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Prevention and health care
    • Studies
View Post
  • 19 min
  • Cardiovascular risk and obesity

Pathomechanisms, secondary prevention and treatment options

    • RX
    • Cardiology
    • CME continuing education
    • Endocrinology and Diabetology
    • Nutrition
    • Sports Medicine
    • Studies
    • Training with partner
View Post
  • 6 min
  • Ventricular arrhythmias

Indication for ICD or WCD?

    • RX
    • Cardiology
    • Congress Reports
    • General Internal Medicine
    • Studies
View Post
  • 3 min
  • Early breast cancer

Overweight and obesity worsen the prognosis

    • Congress Reports
    • Gynecology
    • Oncology
    • Prevention and health care
    • RX
    • Studies
View Post
  • 8 min
  • Psoriasis treatment with biologics

What are the latest trends?

    • Congress Reports
    • Dermatology and venereology
    • Pharmacology and toxicology
    • Rheumatology
    • RX
    • Studies
View Post
  • 4 min
  • Flu vaccination for older people

Benefit of the high-dose influenza vaccine

    • Congress Reports
    • General Internal Medicine
    • Geriatrics
    • Infectiology
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Pathomechanisms, secondary prevention and treatment options
  • 2
    Effect of heat on diabetes technology
  • 3
    Improved quality of care aims for satisfied patients
  • 4
    Dr. ChatGPT: Large language models in everyday clinical practice
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.